Status:
COMPLETED
Central Sleep Apnea Treated by CO2 Supplied by a Novel Device
Lead Sponsor:
State Key Laboratory of Respiratory Disease
Conditions:
Central Sleep Apnea
Eligibility:
All Genders
18-82 years
Phase:
NA
Brief Summary
In general, central sleep apnea is not as common as obstructive sleep apnea but it is common in patients with heart failure. It has been repeatedly shown that central sleep apnea worsens the prognosis...
Detailed Description
Objective: To determine whether the device could improve sleep quality while eliminating CSA during the overnight study. Methods: Patients with central sleep apnea diagnosed by diaphragm EMG will be r...
Eligibility Criteria
Inclusion
- Willing to participate after informed consent
- Males and females, any race and aged≥18yeras
- Objectively confirmed central sleep apnea/Cheyne Stokes Respiration with an apnoea-hypopnoea- index (AHI)≥5/h by overnight polysomnography
Exclusion
- Obstructive sleep apnea
- Severe COPD，FEV1/FVC\<70% and FEV1\<60%
- Chronic CO2 retention with unknown reason
- Severe nasal congestion
- Poor understanding
Key Trial Info
Start Date :
May 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04907058
Start Date
May 20 2021
End Date
September 23 2021
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510230